DavidMFriedlandMD

Oncology • Pittsburgh, PA

Genitourinary Oncology, Hematologic Oncology, Thoracic Cancer

Medical Oncologist at UPMC

Join to view full profile

Dr. Friedland is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Friedland's full profile

Already have an account?

Office
5115 Centre Ave
3rd Floor
Pittsburgh, PA 15232
Phone+1 412-235-1020

Fax+1 412-235-1030
Is this information wrong?

Education & Training

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1992 - 1994
Presbyterian Medical Center of the University of Pennsylvania Health SystemResidency, Internal Medicine, 1989 - 1992
University of Maryland School of MedicineClass of 1989

Certifications & Licensure

PA State Medical License 1991 - 2024
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2013
Top MD Consumers Checkbook

Clinical Trials

Carboxyamidotriazole in Treating Patients With Advanced Kidney Cancer Start of enrollment: 2000 Mar 01
Completed
Phase 2
Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer Start of enrollment: 2009 Sep 01
Completed
Phase 2
Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma Start of enrollment: 2011 Jul 25
Completed
Phase 2

Publications & Presentations

PubMed

13 citations
First-Line Osimertinib in Patients with Treatment-Naive Somatic or Germline EGFR T790M–Mutant Metastatic NSCLC
Katerina Ancevski Hunter, David M. Friedland, Liza C. Villaruz, Timothy F. Burns> ;Journal of Thoracic Oncology. 2018 Jan 1
12 citations
High-dose interleukin 2 in patients with metastatic renal cell carcinoma with sarcomatoid features.
Tala Achkar, Ananth Arjunan, Hong Wang, Melissa Saul, Diwakar Davar, Leonard Joseph Appleman, David M. Friedland, Rahul Atul Parikh> ;Plos One. 2017 Dec 20
31 citations
Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non–small cell lung cancer
Ahmad A. Tarhini, Imran Rafique, Theofanis Floros, Phu Tran, William E. Gooding, Liza C. Villaruz, Timothy F. Burns, David M. Friedland, Daniel P. Petro, Mariya Farooq...> ;Cancer. 2017 Aug 1
124 citations
Results of a Single Institution Experience with Dose-Escalated Chemoradiation for Locally Advanced Unresectable Non-Small Cell Lung Cancer.
Mark E. Bernard, Scott M. Glaser, Beant S. Gill, Sushil Beriwal, Dwight E. Heron, James D. Luketich, David M. Friedland, Mark A. Socinski, Joel S. Greenberger> ;Frontiers in Oncology. 2017 Jan 23
22 citations
A Phase I, Open-Label Study of Trebananib Combined With Sorafenib or Sunitinib in Patients With Advanced Renal Cell Carcinoma
David S. Hong, Michael S. Gordon, Wolfram E. Samlowski, Razelle Kurzrock, Nizar M. Tannir, David M. Friedland, David S. Mendelson, Nicholas J. Vogelzang, Erik Rasmusse...> ;Clinical Genitourinary Cancer. 2014 Jun 1
18 citations
A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer
Suresh S. Ramalingam, Athanasios Kotsakis, Ahmad A. Tarhini, Dwight E. Heron, Roy E. Smith, David M. Friedland, Daniel P. Petro, Luis E. Raez, Julie R. Brahmer, Joel S...> ;Lung Cancer. 2013 Sep 1
7 citations
Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients
Huali Wu, Ramesh K. Ramanathan, Beth A. Zamboni, Sandra Strychor, Suresh S. Ramalingam, Robert P. Edwards, David M. Friedland, Ronald G. Stoller, Chandra P. Belani, La...> ;International Journal of Nanomedicine. 2012 Oct 19
Phase II study of docetaxel (D) and oxaliplatin (O) in recurrent metastatic transitional cell cancer (mTCC) of the urothelial tract.
Chatta GS, Appleman LJ, Friedland D, Tribble G, Davar D> ;J. Clin. Oncol.. 2012-02-10
25 citations
Population Pharmacokinetics of Pegylated Liposomal CKD-602 (S-CKD602) in Patients With Advanced Malignancies
Huali Wu, Ramesh K. Ramanathan, Beth A. Zamboni, Sandra Strychor, Suresh Ramalingam, Robert P. Edwards, David M. Friedland, Ronald G. Stoller, Chandra P. Belani, Laure...> ;Journal of Clinical Pharmacology. 2012 Feb 1
A dose-finding study of a MUC-1 vaccine in conjunction with poly-IC:LC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxy methylcellulose) in immu...
Patel AK, Appleman LJ, Gooding WE, Friedland D, McKolanis J, Salazar AM, Finn OJ, Chatta GS> ;J. Clin. Oncol.. 2011-05-20
Multicenter phase II study of cetuximab (C) with concomitant radiotherapy (RT) followed by consolidation chemotherapy (CT) in locally advanced non-small cell lung canc...
Kotsakis AP, Ramalingam SS, Tarhini AA, Heron DE, Smith R, Friedland D, Petro DP, Raez LE, Brahmer JR, Greenberger JS, Dacic S, Hershberger P, Landreneau RJ, Belani CP...> ;J. Clin. Oncol.. 2011-05-20
36 citations
Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors
William C. Zamboni, Lauren J. Maruca, Sandra Strychor, Beth A. Zamboni, Suresh Ramalingam, Robert P. Edwards, J. K. Kim, Yung Jue Bang, H-Y Lee, David M. Friedland, Ro...> ;Journal of Liposome Research. 2011 May 18
103 citations
Phase II study of everolimus (RAD001) in previously treated small cell lung cancer.
Ahmad A. Tarhini, Athanassios Kotsakis, William E. Gooding, Yongli Shuai, Daniel P. Petro, David M. Friedland, Chandra P. Belani, Sanja Dacic, Athanassios Argiris> ;Clinical Cancer Research. 2010 Dec 1
CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure in...
Wilcox MH, Corey GR, Talbot GH, Thye D, Friedland D, Baculik T> ;J. Antimicrob. Chemother.. 2010-11-01
5 citations
Extraosseous Osteosarcoma of the Esophagus: A Case Report
Rodney E. Wegner, Kevin McGrath, James D. Luketich, David M. Friedland> ;Sarcoma. 2010 Mar 4
32 citations
Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.
William C. Zamboni, S. Strychor, Lauren J. Maruca, Sakkaraiappan Ramalingam, Beth A. Zamboni, Huali Wu, David M. Friedland, Robert P. Edwards, Ronald G. Stoller, Chand...> ;Clinical Pharmacology and Therapeutics. 2009 Nov 1
Phase II study of RAD001 (everolimus) in previously treated small cell lung cancer (SCLC).
Kotsakis AP, Tarhini A, Petro D, Flaugh R, Vallabhaneni G, Belani CP, Friedland D, Argiris A> ;J. Clin. Oncol.. 2009-05-20
Docetaxel and imatinib every 21 days for castration resistant prostate cancer: A phase II trial.
Gillison TL, Appleman LJ, Friedland DM, Evans TL, Lara PN, Gooding WE, Lenzner DE, Strausser HM, Gingrich JR, Chatta GS> ;J. Clin. Oncol.. 2009-05-20
Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced solid tumors.
Wu H, Ramanathan RK, Srychor S, Zamboni BA, Ramalingam S, Edwards RP, Friedland DM, Stoller RG, Belani CP, Zamboni WC> ;J. Clin. Oncol.. 2009-05-20
43 citations
Phase I and Pharmacokinetic Study of Pegylated Liposomal CKD-602 in Patients with Advanced Malignancies
William C. Zamboni, Suresh Ramalingam, David M. Friedland, Robert P. Edwards, Ronald G. Stoller, Sandra Strychor, Lauren J. Maruca, Beth A. Zamboni, Chandra P. Belani,...> ;Clinical Cancer Research. 2009 Feb 15
58 citations
Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases
Sheikh Asim Ali, Wassim McHayleh, Asif Ahmad, Rajesh Sehgal, Molly Braffet, Mohsin Rahman, Ghassan K. Bejjani, David M. Friedland> ;Journal of Neurosurgery. 2008 Aug 1
49 citations
A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies.
Suresh S. Ramalingam, Merrill J. Egorin, Ramesh K. Ramanathan, Scot C. Remick, Rachel P. Sikorski, Theodore F. Lagattuta, Gurkamal Chatta, David M. Friedland, Ronald G...> ;Clinical Cancer Research. 2008 Jun 1
Oxaliplatin and docetaxel in castration-resistant prostate cancer (CRPC) patients treated with up to two prior chemotherapeutic regimens: Updated results of a phase II...
Chatta GS, Feinstein TM, Appleman LJ, Friedland DM, Jacobs SA, Evans TL, Earle MF, Strausser HM, Gooding WE, Lenzner D> ;J. Clin. Oncol.. 2008-05-20
Cytotoxic chemotherapy with androgen deprivation for biochemically recurrent prostate cancer following radical prostatectomy: A retrospective review.
Friedland DM, Feinstein TM, Braffet MJ, Nelson JB> ;J. Clin. Oncol.. 2008-05-20
15 citations
Renal cell carcinoma from a transplanted allograft: two case reports and a review of the literature.
Wassim McHayleh, John P. Morcos, Tong Wu, Ron Shapiro, Samuel A. Yousem, Leonard Joseph Appleman, David M. Friedland> ;Clinical Genitourinary Cancer. 2008 Mar 1
Join now to see all

Press Mentions

Timing of Palliative Care Linked to Better Lung Cancer SurvivalOctober 9th, 2019

Hospital Affiliations

UPMC Presbyterian ShadysidePittsburgh, Pennsylvania
UPMC Magee-Womens HospitalPittsburgh, Pennsylvania
Shadyside CampusPittsburgh, Pennsylvania